Yoannis Imbert-Fernandez
Overview
Explore the profile of Yoannis Imbert-Fernandez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
489
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lypova N, Dougherty S, Clem B, Feng J, Yin X, Zhang X, et al.
Cancer Metab
. 2024 Dec;
12(1):37.
PMID: 39696407
Background: The efficacy of tyrosine kinase inhibitors (TKIs) targeting the EGFR is limited due to the persistence of drug-tolerant cell populations, leading to therapy resistance. Non-genetic mechanisms, such as metabolic...
2.
Imbert-Fernandez Y, Chang S, Lanceta L, Sanders N, Chesney J, Clem B, et al.
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001392
Rapidly proliferative processes in mammalian tissues including tumorigenesis and embryogenesis rely on the glycolytic pathway for energy and biosynthetic precursors. The enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) plays an important regulatory role in...
3.
Lypova N, Dougherty S, Lanceta L, Chesney J, Imbert-Fernandez Y
Cells
. 2021 Aug;
10(7).
PMID: 34359849
Tyrosine kinase inhibitors (TKIs) targeting the kinase domain of the epidermal growth factor receptor (EGFR), such as erlotinib, have dramatically improved clinical outcomes of patients with EGFR-driven non-small cell lung...
4.
Lanceta L, Lypova N, ONeill C, Li X, Rouchka E, Chesney J, et al.
Breast Cancer Res Treat
. 2021 Feb;
186(3):677-686.
PMID: 33599863
Purpose: The management of triple-negative breast cancer (TNBC) remains a significant clinical challenge due to the lack of effective targeted therapies. Inhibitors of the cyclin-dependent kinases 4 and 6 (CDK4/6)...
5.
Ozcan S, Sarioglu A, Altunok T, Akkoc A, Guzel S, Guler S, et al.
Mol Cell Biochem
. 2020 May;
470(1-2):115-129.
PMID: 32415418
Tumor cells increase glucose metabolism through glycolysis and pentose phosphate pathways to meet the bioenergetic and biosynthetic demands of rapid cell proliferation. The family of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFKFB1-4) are key regulators...
6.
Lanceta L, ONeill C, Lypova N, Li X, Rouchka E, Waigel S, et al.
Genes (Basel)
. 2020 Apr;
11(4).
PMID: 32344635
Acquired resistance to cyclin-dependent kinases 4 and 6 (CDK4/6) inhibition in estrogen receptor-positive (ER+) breast cancer remains a significant clinical challenge. Efforts to uncover the mechanisms underlying resistance are needed...
7.
Lypova N, Telang S, Chesney J, Imbert-Fernandez Y
J Biol Chem
. 2019 May;
294(27):10530-10543.
PMID: 31126985
Constitutive activation of the epidermal growth factor receptor (EGFR) because of somatic mutations of the gene is commonly observed in tumors of non-small cell lung cancer (NSCLC) patients. Consequently, tyrosine...
8.
Lypova N, Lanceta L, Gibson A, Vega S, Garza-Morales R, McMasters K, et al.
Cancers (Basel)
. 2019 May;
11(5).
PMID: 31100952
While clinical responses to palbociclib have been promising, metastatic breast cancer remains incurable due to the development of resistance. We generated estrogen receptor-positive (ER+) and ER-negative (ER-) cell line models...
9.
Chesney J, Imbert-Fernandez Y, Telang S, Baum M, Ranjan S, Fraig M, et al.
Melanoma Res
. 2018 Mar;
28(3):250-255.
PMID: 29561296
Talimogene laherparepvec is a genetically modified herpes simplex virus type 1-based oncolytic immunotherapy for the local treatment of unresectable subcutaneous and nodal tumors in patients with melanoma recurrent after initial...
10.
ONeal J, Clem A, Reynolds L, Dougherty S, Imbert-Fernandez Y, Telang S, et al.
Breast Cancer Res Treat
. 2016 Sep;
160(1):29-40.
PMID: 27613609
Purpose: Human epidermal growth factor receptor-2 (HER2) has been implicated in the progression of multiple tumor types, including breast cancer, and many downstream effectors of HER2 signaling are primary regulators...